Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens-Reference-Cited by-同舟云学术

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens

Published:2017-06-26 Issue:15 Volume:1 Page:1159-1166
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Westwood John-Paul¹,Thomas Mari¹,Alwan Ferras¹,McDonald Vickie²,Benjamin Sylvia³,Lester William A.⁴,Lowe Gillian C.⁴,Dutt Tina⁵,Hill Quentin A.⁶,Scully Marie¹

Affiliation:

1. Department of Haematology, University College London Hospital, London, United Kingdom;

2. Centre for Haemostasis and Thrombosis, St. Thomas’ Hospital, London, United Kingdom;

3. National Health Service (NHS) Blood and Transplant Therapeutic Apheresis Services and Oxford University Hospitals Foundation Trust, Oxford, United Kingdom;

4. Comprehensive Care Haemophilia Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;

5. Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool, United Kingdom; and

6. Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Abstract

Key Points Rituximab is effective in preventing relapse in TTP patients in remission with low ADAMTS13 levels. Reduced-dose rituximab (200 mg) is associated with higher rates of re-treatment than the standard dose (375 mg/m2).

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/15/1159/878655/advances008268.pdf

Reference23 articles.

1. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura;Furlan;Baillieres Clin Haematol,1998

2. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura;Tsai;N Engl J Med,1998

3. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura;Scully;Blood,2011

4. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura;Shumak;Ann Intern Med,1995

5. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange;Bandarenko;J Clin Apher,1998

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of lupus nephritis;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome;Blood;2024-09-12

3. Lupus nephritis. Part II, modern ideas about therapy;Rheumatology Science and Practice;2024-09-02

4. KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis. Translated into Russian by E.V. Zakharova;Nephrology and Dialysis;2024-08-13

5. IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29